Split Intein-based Selection for Modified Peptide Binders to SARS-CoV-2 Spike Protein
Invention type: Technology
/
Case number: #22502
Disclosed herein, in some embodiments, non-naturally occurring proteins (e.g., non-naturally occurring modified proteins) that may be useful in the treatment of bacterial and viral infections, including SARS-CoV-2 infection, host cells comprising the same, and methods of treating bacterial and viral infections including SARS-CoV-2 infection.
Researchers
Christopher Voigt
/ Emerson Glassey
/ Andrew King
Departments: Department of Biological Engineering
Technology Areas: Biotechnology: Synthetic Biology / Drug Discovery and Research Tools: Genomics & Proteomics / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living
-
split intein-based selection for peptide binders
United States of America | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.